AAS
RVMD icon

Ameritas Advisory Services’s Revolution Medicines RVMD Stock Holding History

Ameritas Advisory Services’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250
Closed -$11.7K – 1888
2025
Q3 		$11.7K Hold
250
– – ﹤0.01% 1605
2025
Q2 		$9.2K Buy
+250
New +$9.6K ﹤0.01% 2046

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ameritas Advisory Services's RVMD Position: Q4 2025 in Review

Ameritas Advisory Services sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 250 shares — an estimated $11.7K sold.

Ameritas Advisory Services first reported a position in RVMD in Q2 2025 and held it in 2 quarters. The position peaked at $11.7K in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Ameritas Advisory Services reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 250 Revolution Medicines shares in Q4 2025, an estimated $11.7K.
  • Ameritas Advisory Services first reported a position in Revolution Medicines in Q2 2025 and held it in 2 quarters.
  • Ameritas Advisory Services's Revolution Medicines position peaked at $11.7K in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.